DLBCL with amplification of JAK2/PD-L2 exhibits PMBCL-like CNAs pattern, and demonstrates unfavorable outcome resembling those with MYD88 L265P mutation. This evidence concerns the gene JAK2 and diffuse large B-cell lymphoma.